Jeffrey Bluestone
President & CEO @ Parker Institute for Cancer Immunotherapy
San Francisco, United States
Jeffrey Bluestone is a funding round investor at Parker Institute for Cancer Immunotherapy in San Francisco focused on Health Care and Biotechnology. Jeffrey Bluestone, PhD is CEO and President, Parker Institute for Cancer Immunotherapy and the A.W. and Mary Margaret Clausen Distinguished Professor at UCSF. A leading researcher in immune tolerance and T-cell activation, he has developed multiple immunotherapies including the first FDA-approved drug targeting T-cell co-stimulation in autoimmunedisease and organ transplantation, and CTLA-4 antagonist drugs approved to treat metastatic melanoma. As an academic leader on a national and international scale he was founding director of the Immune Tolerance Network, the largest NIH-funded multicenter clinical immunology research program testing novel immunotherapies in transplantation, autoimmunity, and asthma/allergy. As former UCSF Executive Vice Chancellor and Provost, and former Director of the UCSF Diabetes Center, he has authored over 400 peer-reviewed publications and received numerous awards including election to the American Academy of Arts and Sciences, the National Academy of Medicine and as member of Vice President Biden’s Cancer Moonshot Blue Ribbon Panel.
- Total investments:
- 1
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Jeffrey Bluestone invests in
Stages Jeffrey Bluestone invests in
Countries Jeffrey Bluestone invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 1 (100%)
- Biotechnology 1 (100%)
- Clinical Trials 1 (100%)
- Health Diagnostics 1 (100%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
ImaginAb
|
ImaginAb is a biotechnology company focused on developing a new class of highly targeted diagnostic imaging agents based on engineered antibody fragments. ImaginAb's platform technology enables the rapid engineering of antibodies into fragments that retain the parental antibody but are immunologically passive and kinetically-optimized forclinical imaging. This combination of superior specificity and kinetics enables ImaginAb to generate agents that can address the unmet needs in diagnosis and patient selection for therapeutics. | $8M / Sep 14, 2017 |
Co-Investors
The Parker Institute for Cancer Immunotherapy brings together the best scientists, clinicians, and industry partners. The company strives to build a smarter and more coordinated cancer immunotherapy research effort to save lives.
Parker Institute for Cancer Immunotherapy Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Jeffrey Bluestone
President & CEO
|
|||
Sean Parker
Founder and Chairman
|
|||
Charles Michael Yim
Donor
|
|||
Crystal Mackall
Director, Parker Institute for Cancer Immunotherapy at Stanford
|
|||
Crystal Mackall
Director, Parker Institute for Cancer Immunotherapy at Stanford
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Jeffrey Bluestone invest in?
Jeffrey Bluestone invests primarily in Health Care, Biotechnology and Clinical Trials startups, most often at Funding Round stage. Most of the 1 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Jeffrey Bluestone?
Public channels for Jeffrey Bluestone include LinkedIn, X (Twitter) and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Jeffrey Bluestone last invest?
The most recent investment recorded for Jeffrey Bluestone closed in Sep 2017. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
